Money Control Place
  • Politics
  • Business
  • Stocks
  • Investing
  • Politics
  • Business
  • Stocks
  • Investing

Money Control Place

Investing

Completion of First Triage Test Clinical Validation Study

by November 9, 2023
November 9, 2023
Completion of First Triage Test Clinical Validation Study

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the publication of an article on its triage test for ovarian cancer.

Highlights

Results from the first clinical validation study of the CleoDX Triage Test, performed in a 334 patient cohort, have been published in the peer-reviewed journal “Cancers”The article, entitled ‘A novel predictive multi-marker test for the pre-surgical identification of ovarian cancer’ provides a detailed overview of the high performance of Cleo’s ovarian cancer diagnostics testThe article concluded that Cleo’s ovarian cancer test:Was highly accurate with 95% sensitivity1 / 95% specificity2;Correctly discriminated malignant from benign samples; andOut-performed and was superior to current clinical methods.Peer-review provides important validation of Cleo’s technology and commercial strategy, targeting the surgical triage market where accurate and sensitive identification of malignant tumours is essential.

PEER REVIEWED PUBLICATION

Cleo’s first clinical validation study for its ovarian cancer triage test has been published in the peer- reviewed international journal ‘Cancers’. The results confirm the high accuracy of the CleoDX Triage Test, which was independent of menopausal status, and showed that it out-performed the two most widely used clinical scoring systems (the “Risk of Malignancy Index” and “Risk of Malignancy Algorithm”) for discriminating benign from malignant ovarian disease.

A copy of the publication is available here: https://www.mdpi.com/2072-6694/15/21/5267

Moreover, the CleoDX surgical triage test correctly identified 81% of early-stage cancer patients in the cohort.

Commenting on the publication, Cleo Chief Scientific Officer, Dr Andrew Stephens, said:

“These results confirm that our core technology is robust and accurate, and most importantly can identify cancers at an early stage. These results strongly support our planned further development of this core technology aimed at ovarian cancer screening in the longer term”.

CLEO Chief Executive, Richard Allman, added:

“This is an important step forward as we work towards our goal of an FDA approved triage test. I look forward to providing further updates to the market as we progress through our development program.”

The next step in development will confirm functionality of the commercially available kits in an independent clinical trial, the results of which will be submitted to the FDA for regulatory approval. Cleo anticipates commencement of this trial before the end of CY 2023.

OPPORTUNITY FOR CLEO AND OVARIAN CANCER DIAGNOSTICS MARKET

At present there is no clinically routine pre-surgical method for reliable evaluation and differentiation of benign vs malignant ovarian cancer tumours. Radical surgery is the cornerstone of cancer management, with complete hysterectomy being the norm. Removal of the ovaries, however, predisposes women to multiple co-morbidities including increased risk of cardiovascular disease, dementia and certain cancers amongst others. There is a clear need to differentiate benign vs malignant cases pre-surgically to enhance patient outcomes.

Cleo has defined a staged execution strategy to deliver it’s simple blood test which is focused on three key markets across pre-surgical triage testing, high-risk/recurrence detection, and broader screening programs. Achieving a positive outcome here from a peer-reviewed publication, has a material impact on the Company’s pathway with respect to the initial triage market. The Company will now use the publication of its test performance to further define the scope of the triage market.

Click here for the full ASX Release

This post appeared first on investingnews.com
0
FacebookTwitterGoogle +Pinterest
previous post
Americans are unusually down on a solid economy. So far, they aren’t spending — or voting — like it.
next post
Freegold Intersects 1.44 g/t Au over 31.4 m at Golden Summit

Related Posts

Editor’s Picks: Gold Price Faces Pressure, Uranium Bulls...

October 9, 2023

Danielle DiMartino Booth: US Economy at Precipice —...

March 28, 2025

Multiple Work Programs Underway and Planned at Radium...

April 12, 2024

European Lithium

December 29, 2023

Deep Drilling Hits Visible Gold Over 1km Deep...

April 9, 2024

Crypto Market Recap: WLFI Unveils Strategic Token Reserve

February 15, 2025

5 Top Weekly TSXV Stocks: Dynasty Gold Rises...

June 26, 2023

Energy Fuels Enters into MOU to Secure Near-Term,...

December 29, 2023

Should You Invest in Silver Bullion? (Updated 2024)

May 6, 2024

Crypto Market Recap: Swiss Central Bank Dismisses Bitcoin...

April 26, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Confused by the Market? Let the Traffic Light Indicator Guide You

    • Which Will Hit First: SPX 6100 or SPX 5100?

    • Investment Portfolio Feeling Stagnant? Transform Your Path Today

    • Where the Market Goes Next: Key Resistance Levels + Top Bullish Stocks to Watch Now

    • Recession Ahead? Sector Rotation Model Warns of Rising Risk

    • Crypto Market Recap: Bitcoin Breaks US$100,000 as ETF Inflows Rise, Coinbase Makes US$2.9 Billion Power Play

    Categories

    • Business (1,183)
    • Investing (2,412)
    • Politics (3,699)
    • Stocks (1,558)
    • Uncategorized (20)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: MoneyControlPlace.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 moneycontrolplace.com | All Rights Reserved